Cirrhosis: Clinical sciences

Last updated: January 30, 2025

Cirrhosis: Clinical sciences

Block 9 Gastrointestinal partial

Block 9 Gastrointestinal partial

Colon histology
Esophagus histology
Gallbladder histology
Liver histology
Pancreas histology
Small intestine histology
Stomach histology
Gastroesophageal reflux disease (GERD)
Barrett esophagus
Eosinophilic esophagitis (NORD)
Esophageal cancer
Mallory-Weiss syndrome
Esophageal atresia and tracheoesophageal fistula: Year of the Zebra
Achalasia
Achalasia: Year of the Zebra
Esophageal disorders: Clinical
Esophageal disorders: Pathology review
Esophagitis: Clinical
Gastroesophageal reflux disease (GERD): Clinical
Gastroesophageal reflux disease: Clinical sciences
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Plummer-Vinson syndrome
Gastrointestinal bleeding: Clinical
Gastrointestinal bleeding: Pathology review
Diffuse esophageal spasm
Scleroderma: Pathology review
Scleroderma
Boerhaave syndrome
Pediatric gastrointestinal bleeding: Clinical
Jaundice
Jaundice: Pathology review
Jaundice: Clinical
Neonatal jaundice: Clinical
Approach to jaundice (unconjugated hyperbilirubinemia): Clinical sciences
Approach to jaundice (conjugated hyperbilirubinemia): Clinical sciences
Cholestatic liver disease
Cirrhosis: Clinical
Hepatitis B and Hepatitis D virus
Viral hepatitis: Pathology review
Viral hepatitis: Clinical
Viral hepatitis
Cirrhosis
Cirrhosis: Clinical sciences
Cirrhosis: Pathology review
Portal hypertension
Pulmonary arterial hypertension (NORD)
Approach to ascites: Clinical sciences
Pancreatitis: Clinical
Hepatocellular carcinoma
Hepatocellular adenoma
Peptic ulcer
Peptic ulcer disease: Clinical sciences
Peptic ulcers and stomach cancer: Clinical
Zollinger-Ellison syndrome
Approach to melena and hematemesis: Clinical sciences
Acid reducing medications
Antidiarrheals
Acute pancreatitis
Pancreatitis: Pathology review
Chronic pancreatitis
Chronic pancreatitis: Clinical sciences
Pancreatic cancer
Pancreatic cancer: Clinical sciences
Pancreatic neuroendocrine neoplasms
Acute cholecystitis
Neuroendocrine tumors of the gastrointestinal system: Pathology review
MEN syndromes: Clinical
Multiple endocrine neoplasia: Pathology review
Diabetes mellitus: Clinical
Diabetes mellitus
Diabetes mellitus: Pathology review
Diabetes mellitus (Type 2): Clinical sciences
Bowel obstruction: Clinical
Bowel obstruction
Large bowel obstruction: Clinical sciences
Small bowel obstruction: Clinical sciences
Irritable bowel syndrome
Inflammatory bowel disease: Pathology review
Inflammatory bowel disease: Clinical
Inflammatory bowel disease (Crohn disease): Clinical sciences
Short bowel syndrome (NORD)
Small bowel ischemia and infarction
Inflammatory bowel disease (ulcerative colitis): Clinical sciences
Diverticular disease: Clinical
Abdominal hernias
Hernias: Clinical
Inguinal hernia
Abdominal trauma: Clinical
Intussusception
Rotavirus
Congenital gastrointestinal disorders: Pathology review
Intestinal atresia
Diarrhea: Clinical
Yersinia enterocolitica
Escherichia coli
Malabsorption: Clinical
Malabsorption syndromes: Pathology review
Celiac disease
Tropical sprue
Whipple's disease
Colorectal polyps and cancer: Pathology review
Diverticular disease: Pathology review
Gallbladder disorders: Pathology review
Biliary atresia
Crigler-Najjar syndrome
Gilbert's syndrome
Gallstone ileus
Colorectal cancer
Colorectal polyps
Femoral hernia
Crohn disease
Ulcerative colitis
Microscopic colitis
Ischemic colitis
Carcinoid syndrome
Diverticulosis and diverticulitis
Gastroenteritis
Zenker diverticulum
Gastritis
Gastric cancer
Gastric dumping syndrome
Oral candidiasis
Oral cancer
Norovirus
Anal fissure
Anal fistula
Anal fissure: Clinical sciences

Decision-Making Tree

Transcript

Watch video only

Cirrhosis refers to chronic progressive fibrotic changes of the liver parenchyma that occur in response to chronic injury and inflammation. A variety of conditions can cause this injury, including viral hepatitis, chronic alcohol use, autoimmune disease, and hereditary conditions like hemochromatosis or alpha-1 antitrypsin deficiency, and the ensuing fibrotic changes eventually impair liver function.

Early in the disease process, cirrhotic patients remain relatively asymptomatic and are considered to have compensated cirrhosis, while those who present with symptoms are considered to have decompensated cirrhosis. Complications due to cirrhosis include spontaneous bacterial peritonitis, ascites, variceal bleeding, hepatic encephalopathy, and hepatorenal syndrome, which can be life-threatening, therefore it’s important to quickly identify these patients who may suddenly decompensate.

Now, if you suspect cirrhosis, first perform an ABCDE assessment to determine if your patient is unstable. Keep in mind that cirrhosis is never unstable unless it's decompensated and the patient develops complications. If this is the case, you may need to secure the airway, breathing, and circulation, which might require intubating the patient, and starting mechanical ventilation. Next, obtain IV access and, if your patient is hypotensive, start IV fluids for volume resuscitation. If there are signs of blood loss, they might even need a transfusion of blood products, such as packed red blood cells, platelets, and even fresh frozen plasma. You should also continuously monitor vital signs.

Additionally, if you suspect decompensated cirrhosis complications, it’s important to identify the underlying cause and complication. To do so, start by performing a focused history and physical examination, and depending on the suspected complication, you may want to order labs or ultrasound.

Alright, if your patient presents with abdominal distension and a palpable fluid wave, and ultrasound reveals free fluid in the peritoneal cavity, that’s ascites. On the other hand, if your patient has fever and abdominal pain, and labs reveal a positive ascitic fluid culture with PMN predominance, your patient has spontaneous bacterial peritonitis. If you notice signs of blood loss, such as melena, hematochezia, and hematemesis, with anemia on labs, think of variceal bleeding.

If instead your patient presents with neurologic signs, such as altered mental status and flapping tremor, also known as asterixis, that’s hepatic encephalopathy. Lastly, if your patient has dark urine and oliguria, and their labs show elevated creatinine, but there’s no evidence of an intrinsic kidney disease, you should think of hepatorenal syndrome, keeping in mind that it’s a diagnosis of exclusion. Once you’ve identified your patient’s specific complication, the management includes treatment of the underlying cause and complication, including consulting the appropriate specialists and the surgical team. For definitive treatment, consider liver transplantation.

Now, here’s a clinical pearl to keep in mind! Active variceal bleeding in a cirrhotic patient carries a high mortality rate and can be challenging to manage. Not only is the presence of variceal bleeding associated with advanced disease in the first place, but variceal bleeding, by its very nature, is under increased pressure from portal hypertension. Further, cirrhotic patients typically have coagulopathy and thrombocytopenia, so their ability to clot is impaired, and gaining control of the bleeding is not easy. Hypotension and hemorrhagic shock may ensue, and volume resuscitation is challenging since albumin is already low. So, you should use colloids, albumin, and blood products to achieve hemodynamic stability. Finally, immediately call the endoscopy team to stop the bleeding.

Ok so let’s go back to the ABCDE assessment where your patient is instead stable and cover compensated cirrhosis. First, obtain a focused history and physical examination, as well as labs, including CBC, CMP, PT, PTT, and possibly ammonia level. In compensated cirrhosis, the remaining healthy liver parenchyma is still able to compensate for systemic demands of liver function. As a result, these patients are usually asymptomatic, and they haven’t developed overt complications from cirrhosis; some may present with varices, but they haven’t had any episodes of variceal bleeding.

Now, since these patients are asymptomatic, they may come to clinical attention on routine lab evaluation. Lab findings might include elevated hepatic transaminases AST and ALT, alkaline phosphatase or ALP, bilirubin, clotting studies like PT and PTT, and ammonia levels; as well as decreased albumin and thrombocytopenia. The combination of these signs, symptoms, and lab findings should lead you to suspect compensated cirrhosis. To confirm the diagnosis, obtain an abdominal ultrasound, as well as ultrasound with elastography. Additionally, you can obtain a liver biopsy, which is the gold standard for diagnosis. Abdominal ultrasound will reveal a small nodular liver, as well as the absence of ascites, while ultrasound with elastography may show increased liver stiffness. Lastly, liver biopsy is not always done, but it may help confirm the diagnosis by showing regenerative nodules and fibrotic tissue.

Okay, now that you’ve confirmed the diagnosis of compensated cirrhosis, let's turn our attention to management. First, you’ll want to treat the underlying cause of cirrhosis. For example, if your patient has viral hepatitis, start them on antiviral medications; or if they use alcohol, encourage abstinence and get them specialty treatment for alcohol use disorder. Also be sure to encourage additional lifestyle modifications, like weight loss for those with steatohepatitis, as well as avoiding heavily processed foods, and limiting hepatotoxic and nephrotoxic medications, like NSAIDs.

Offer vaccination for Hepatitis A and B, and screen for hepatocellular carcinoma every 6 months by obtaining an ultrasound with or without measuring blood concentrations of alpha-fetoprotein. You should also screen for esophageal varices at the time of diagnosis and every 2 to 3 years thereafter. In addition, calculate your patient’s MELD-Na score and Child-Pugh scores. Lastly consult the surgical team for transfer to a transplant center as your patient could be a candidate for liver transplant. Transplant is the only definitive treatment for cirrhosis.

Sources

  1. "AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis" Hepatology (2023)
  2. "AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis" Hepatology (2022)
  3. "Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases" Hepatology (2021)
  4. "Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation" Am Fam Physician (2006)
  5. "Precipitating factors and the outcome of hepatic encephalopathy in liver cirrhosis" J Coll Physicians Surg Pak (2010)